Abstract
Growth retardation is one of the significant changes in chronic kidney disease (CKD) and is associated with increased morbidity and mortality. Disturbances in growth hormone (GH) are held responsible for several complications in CKD. GH is a protein based peptide hormone which directly or indirectly regulates renal functions to ensure homeostasis. We investigated the effects of growth hormone on plasminogen activators (PA) in rat kidney, PA and plasminogen activator inhibitor (PAI), glucose and fibrinogen in plasma and serum lipid profile. Rats were injected daily with 250 mU GH kg-1 body weight subcutaneously for one week. Growth hormone treatment increased PA activity significantly in rat kidneys as compared to controls. No changes were seen in PA, PAI and fibrinogen levels in the plasma of two groups of rats. There was significant decrease in plasma glucose, total cholesterol and LDL-cholesterol levels in serum of treated group resulting in the decrease of HDL/LDL and total cholesterol/cholesterol ratios. However, triglycerides and VLDL showed significant higher activity in the serum of treated group as compared to controls. Our data suggests that GH administration might improve renal function by increasing PA activity in kidney as well as by reducing the cholesterol content in blood. GH may be effective in improving growth failure as it helps to maintain the normal homeostatic balance.
References
Krysiak R, Gdula-Dymek A, Bednarska-Czerwińska A, Okopień B. Growth hormone therapy in children and adults. Pharmacol Rep. 2007;59:500–16.
Lanes R. Long-term outcome of growth hormone therapy in children and adolescents. Treat Endocrinol. 2004;3(1):53–66.
Miller SB, Moulton M, O’Shea M, Hammerman MR. Effects of IGF-I on renal function in end-stage chronic renal failure. Kidney Int. 1994;46:201–7.
Møller N, Schmitz O, Pørksen N, Møller J, Jørgensen JO. Dose-response studies on the metabolic effects of a growth hormone pulse in humans. Metabolism. 1992;41(2):172–5.
Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009;30(2):152–77.
Verheijen JH, Chang GTG, Kluft C. Evidence for the occurance of a fast acting inhibitor of PA in human plasma. Thromb Haemost. 1984;51(3):392–5.
Ratnoff OD, Menzie C. A new method for the determination of fibrinogen in small samples of plasma. J Lab Clin Med. 1951;37:316–20.
Zlatkis A, Zak B, Boyle AJ. A new method for the direct determination of serum cholesterol. J Lab Clin Med. 1953;41(3):486–92.
Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem. 1973;19(5):476–82.
Lopex-Vireflla MFL, Stone PG, Coldwell JA. Serum HDL in diabetic patients. Diabetologia. 1977;13:285–91.
Bansal DD, MacGregor RR. Calcium regulated secretion of tPA and PTH from human parathyroid. J Clin Endocrinol Metab. 1992;74:266–71.
Mahesh S, Kaskel F. Growth hormone axis in chronic kidney disease. Pediatr Nephrol. 2008;23(1):41–8.
Fine NR. Etiology and treatment of growth retardation in children with CKD and end stage renal disease: a historical perspective. Pediatr Nephrol. 2010;25(4):725–32.
Brentjens JR. Glomerular procoagulant activity and glomerulonephritis. Lab Invest. 1987;57(2):107–11.
Caidahl K, Edén S, Bengtsson BA. Cardiovascular and renal effects of growth hormone. Clin Endocrinol (Oxf). 1994;40(3):393–400.
Kluft C, Jie AF, Rijken DC, Verheijen JH. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1). Thromb Haemost. 1988;59(2):329–32.
Feller DD, Neville ED. Insulin-like effect of bovine growth hormone in vivo as demonstrated by oxidation of 14C-U-glucose in diabetic rats. Physiol Chem Phys. 1978;10(4):291–304.
Azzarito C, Boiardi L, Zini M, Agosti A, Biacchessi M, Biagi R, Portioli I. Short and long-term effects of growth hormone treatment on lipid, lipoprotein, and apolipoprotein levels in short normal children. Horm Metab Res. 1994;26(9):432–5.
Rudling M, Norstedt G, Olivecrona H, Reihnér E, Gustafsson JA, Angelin B. Importance of growth hormone for the induction of hepatic low density lipoprotein receptors. Proc Natl Acad Sci USA. 1992;89(15):6983–7.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bubber, P., Sharma, A., Chauhan, A. et al. Effect of Growth Hormone on Plasminogen Activator and Inhibitor Activity in Rat. Ind J Clin Biochem 28, 193–196 (2013). https://doi.org/10.1007/s12291-012-0249-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12291-012-0249-0